Peripheral artery disease: current insight into the disease and its diagnosis and management.
Peripheral artery disease (PAD), which comprises atherosclerosis of the abdominal aorta, iliac, and lower-extremity arteries, is underdiagnosed, undertreated, and poorly understood by the medical community. Patients with PAD may experience a multitude of problems, such as claudication, ischemic rest pain, ischemic ulcerations, repeated hospitalizations, revascularizations, and limb loss. This may lead to a poor quality of life and a high rate of depression. From the standpoint of the limb, the prognosis of patients with PAD is favorable in that the claudication remains stable in 70% to 80% of patients over a 10-year period. However, the rate of myocardial infarction, stroke, and cardiovascular death in patients with both symptomatic and asymptomatic PAD is markedly increased. The ankle brachial index is an excellent screening test for the presence of PAD. Imaging studies (duplex ultrasonography, computed tomographic angiography, magnetic resonance angiography, catheter-based angiography) may provide additional anatomic information if revascularization is planned. The goals of therapy are to improve symptoms and thus quality of life and to decrease the cardiovascular event rate (myocardial infarction, stroke, cardiovascular death). The former is accomplished by establishing a supervised exercise program and administering cilostazol or performing a revascularization procedure if medical therapy is ineffective. A comprehensive program of cardiovascular risk modification (discontinuation of tobacco use and control of lipids, blood pressure, and diabetes) will help to prevent the latter.
Olin
Jeffrey W
JW
Zena and Michael A Wiener Cardiovascular Institute, Marie-Josée and Henry R Kravis Center, Cardiovascular Health, Mount Sinai Medical Center, New York, NY 10029, USA. jeffrey.olin@mountsinai.org
Sealove
Brett A
BA
D055109:Ankle Brachial Index; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D000077407:Cilostazol; D003937:Diagnosis, Differential; D018450:Disease Progression; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007383:Intermittent Claudication / Q000209:etiology; D018810:Magnetic Resonance Angiography; D008403:Mass Screening / Q000379:methods; D010431:Pentoxifylline / Q000627:therapeutic use; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D040242:Risk Reduction Behavior; D013777:Tetrazoles / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D018616:Ultrasonography, Doppler, Duplex; D014481:United States / Q000453:epidemiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol; D010431:Pentoxifylline